ROR1 and B-cell chronic lymphocytic leukemia: CLL cells are in most cases highly ROR1 positive (Baskar et al., 2008; Fukuda et al., 2008) and there are currently several therapies in development that target ROR1 (Hudecek et al., 2010; Choi et al., 2015).